Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02288234 · ClinicalTrials.gov registry record
Telavancin Observational Use Registry (TOUR)
A clinical trial, sponsored by Cumberland Pharmaceuticals.
- Completed
- Registry status
- 1,063
- Enrollment target
NCT02288234: Completed study, sponsored by Cumberland Pharmaceuticals.
NCT02288234 is a clinical trial that has completed, run by Cumberland Pharmaceuticals. The registered enrollment target is 1,063 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02288234 has completed, sponsored by Cumberland Pharmaceuticals.
- COMPLETED
- Registry status
- 1,063 participants
- Enrollment target
Study Summary
The telavancin observational use registry (TOUR) will collect data to support study of the efficacy, safety, and pattern of use of telavancin in hospital-based inpatients and in outpatients being treated in infusion centers who are receiving clinician directed telavancin therapy.
Primary Outcome
defined as the number of days between initiation of telavancin therapy and date of cure, where cure is defined as the resolution of the signs and symptoms of infection and/or no need for additional antibiotic therapy, or clearance of the infection with a negative culture result \[Mohr 2009\]
Interventions
- DRUG Vibativ
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,063 participants |
| Start Date | 2014-11 |
| Est. Completion | 2017-10 |
What the finished NCT02288234 record still lists
NCT02288234 is an observational study that tracks outcomes without assigning an intervention. Its 1,063 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Vibativ is the first listed.
NCT02288234 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02288234 about?
NCT02288234 is a clinical study titled "Telavancin Observational Use Registry (TOUR)". The telavancin observational use registry (TOUR) will collect data to support study of the efficacy, safety, and pattern of use of telavancin in hospital-based inpatients and in outpatients being treated in infusion centers who are receiving clinician directed telavancin therapy.
What is the current status of trial NCT02288234?
This trial is currently completed. The enrollment target is 1,063 participants. The study started on 2014-11. Estimated completion is 2017-10.
What interventions are being tested in trial NCT02288234?
The interventions under investigation include: Vibativ (DRUG).
Who is sponsoring clinical trial NCT02288234?
This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04165798 · 1,065 participants
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
- NCT05520762 · 1,060 participants · NA
Hospital Airway Resuscitation Trial
- NCT05911568 · 1,060 participants
Treatment With Endovascular Intervention for STroke Patients With Existing Disability
- NCT07140172 · 1,060 participants · NA
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia